Company Overview
TG Therapeutics, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases within the United States and international markets. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning it among entities focused on advanced therapeutic interventions rather than generic pharmaceutical manufacturing. Its operational scale is defined by a market capitalization of $4.85B, an annual revenue of $616.29M, and an employee base of 399 individuals. These figures indicate that the company has achieved a significant valuation relative to its current revenue generation, suggesting a high market premium often associated with firms in the biotechnology sector that possess valuable intellectual property pipelines.
Financial Health
The company reported a revenue of $616.29M and a net income of $447.18M over the trailing twelve months, supported by an EBITDA of $123.38M. The substantial gap between the $616.29M revenue and the $447.18M net income reveals an exceptionally efficient cost structure where operating expenses and taxes are absorbed well below 30% of total revenue. However, the free cash flow stands at $-43,978,876, indicating that despite reported profitability, the company is currently investing heavily in operations, R&D, or capital expenditures that exceed its cash generation from daily activities. The gross margin is reported at 83.7%, reflecting the high-margin nature of biopharmaceutical products where manufacturing costs are a small fraction of the sales price. The operating margin of 26.2% and profit margin of 72.6% further demonstrate strong operational efficiency and effective cost control relative to sales volume. In terms of liquidity and leverage, the company holds $141.97M in cash against $254.40M in debt, resulting in a debt-to-equity ratio of 39.26, which suggests a leveraged balance sheet typical for growth-stage biotechs that have recently achieved commercial traction. The current ratio of 4.10 indicates robust short-term liquidity, as current assets are more than four times current liabilities, providing ample buffer for meeting immediate obligations. Management effectiveness is highlighted by a return on equity of 102.8% and a return on assets of 9.4%, signaling that the company generates substantial returns on shareholder capital and utilizes its asset base efficiently.
Valuation Assessment
The trailing twelve-month P/E ratio is 10.96, while the forward P/E is 12.33, implying that the market expects earnings to grow slightly in the future to justify a higher multiple relative to current earnings levels. The price-to-book ratio stands at 6.71, indicating that the market values the company at a significant premium over its net asset book value, a common characteristic for firms with intangible assets like patents and drug pipelines. Alternative valuation metrics such as the price-to-sales ratio of 7.87 and an EV/EBITDA of 37.25 suggest that investors are pricing the stock based on future growth potential and revenue scalability rather than current earnings alone. The 52-week high is $46.48 and the 52-week low is $25.28, meaning the stock is trading within a range that reflects significant volatility and recent price discovery. The beta value is 1.86, which indicates that the stock's price volatility is nearly double that of the broader market, making it sensitive to shifts in investor sentiment regarding biotechnology sectors.
Growth & Income
Revenue growth for the trailing twelve months is 78.0%, whereas earnings growth is -6.1%, indicating that while top-line sales are expanding rapidly, earnings are currently contracting, likely due to increased operating expenses or one-time costs associated with scaling commercialization. For non-dividend payers like TG Therapeutics, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all its earnings back into research, development, and commercial expansion rather than distributing cash to shareholders. This approach aligns with the biotechnology industry standard where capital retention is prioritized to fund the high costs of clinical trials and market entry for new treatments. The overall growth and income profile is characterized by aggressive revenue expansion paired with a lack of current dividend income, reflecting a strategy focused on long-term asset appreciation and pipeline development rather than immediate income distribution.